Virtual Reality Aniseikonia and Metamorphopsia Testing

Conditions

• Aniseikonia
• Metamorphopsia

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Aegenta VR — DEVICE
  The Aegenta VR system is a custom software application designed to operate with a virtual reality (VR) headset platform, such as a smartphone paired with a Google Cardboard V2 viewer. The application presents visual stimuli to each eye and allows users to identify perceived distortions and magnification changes. These responses are used to generate quantitative measures of metamorphopsia and aniseikonia.

Study Details

The purpose of this study is to assess whether the use of small, lightweight, portable virtual reality headset devices can provide a more accessible, reliable, contained, and convenient testing environment compared to previous platforms. Many tests only assess distortions in one plane or meridian and may have confounding effects from factors such as external stimuli or the use of colored filters to selectively display images to each eye. The investigators hypothesize that this device will help minimize, if not get rid of, a lot of these confounding factors that exist currently.

Key Dates

First listed

Sep 24, 2026

Start date

Aug 4, 2026

Status verified

Sep 2026

Primary completion

Jun 30, 2028

Completion

Jun 30, 2030

Study Design

Enrollment

100 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DEVICE_FEASIBILITY

Arms

• Experimental: Amsler-negative participants
  Individuals without retinal pathology and without reported visual distortion on the Amsler grid will undergo testing with the Aegenta VR device in addition to established clinical assessments used to evaluate metamorphopsia and aniseikonia.
• Experimental: Amsler-positive participants
  Individuals with retinal pathology associated with visual distortion, including epiretinal membrane (ERM), age-related macular degeneration (AMD), diabetic macular edema (DME), central serous retinopathy (CSR), or cystoid macular edema (CME), who report distortion on the Amsler grid, will undergo testing with the Aegenta VR device in addition to established clinical assessments used to evaluate metamorphopsia and aniseikonia.

Primary Outcome Measure

Aegenta M-Test Score [ Time Frame: Day 0 ]

Central Contacts

• Nitish Mehta, MD
  212-263-2573
  [email protected]
• Tonya Robin
  929-455-5041
  [email protected]

Locations (1)

Find similar trials in New York, NY